A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Project Details

StatusActive
Effective start/end date12/12/22 → 31/12/25

Funding

  • Syneos Health Australia: A$95,000.00